跳至主要内容
临床试验/CTRI/2023/10/058514
CTRI/2023/10/058514尚未招募Unknown

Evaluation of effectiveness and safety of oral tofacitinib in patients with Parthenium dermatitis: A prospective interventional open label study - NI

AIIMS, New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients with airborne contact dermatitis with positive patch test to Parthenium, having a Parthenium Dermatitis Severity Score (PDSS) of more than or equal to 10.
  • 2. Patients more than or equal to 18 years of age.
  • 3. Consenting patients who are willing to undergo treatment and report for follow up.

排除标准

  • 1. Patients with significant and active liver, renal or haematological disease.
  • 2. Patients < 18 years of age.
  • 3. Pregnant and lactating females.
  • 4. Patients with active or latent TB.
  • 5. Patients with a lymphocyte count less than 500 cells/mm3, an absolute neutrophil count less than 1000 cells/mm3, or hemoglobin level less than 9 g/dL.
  • 6. Patients with active infections.
  • 7. Patients with history of thromboembolic phenomenon or on anticoagulants
  • 8. Patients on immunosuppressive therapy in the last 4 weeks.

研究者

发起方
AIIMS, New Delhi

相似试验